indicate novel transcription, were rigorously addressed using a cohybridization strategy with matched, labeled genomic DNA from the same five individuals (Supplementary Methods). Our analysis strongly suggests that, other than MYC itself, the genomic interval containing the CRC risk variant is devoid of transcription (NCBI GEO GSE16228, Supplementary Fig. 1 and Supplementary Table 1 ).
Given the absence of expression, we assessed whether this region acts as an enhancer. We conducted site-specific chromatin immunoprecipitation (ChIP) assays with antibodies recently demonstrated to mark enhancers 5, 6 , including p300, H3K4me1 and H3K4me3, in the CRC cell line Colo205 (for primer sequences, see Supplementary  Table 2 ). Colo205 is heterozygous for rs6983267. The emergent chromatin signature ( Fig. 1a ) supports enhancer function, showing differential enrichment of H3K4me1 relative to H3K4me3 (ref. 5) as well as enrichment of p300 and RNApolII compared to a control region 6 . To evaluate enhancer activity, we cloned a 1,538-bp region flanking the SNP into a reporter vector (Supplementary Methods). Luciferase assays demonstrated that the 8q24 CRC risk region functions as an enhancer (Fig. 1b) . To evaluate whether enhancer activity was allele specific, we compared the G risk allele to the T allele in a luciferase reporter assay. We observed significantly increased reporter activity with the G allele (P ¼ 0.024; Fig. 1c ). These data are consistent with reporter data generated by Tuupanen et al. in a companion study 7 . Thus, epigenetic and reporter assay data demonstrate that the CRC risk region functions as an enhancer and that the CRC risk variant drives luciferase activity in an allelespecific manner.
The rs6983267 SNP (underlined base) is located within a TCF (T-cell factor) consensus binding sequence (A/T)(A/T)CAA(A/T)GG. Indeed, the main transcriptional effector of Wnt signaling and the partner for b-catenin coactivation in CRC is the sequence-specific DNA-binding protein TCF7L2 (refs. 8-10). Genome-wide ChIP-chip analysis in the LS174T cell line (a CRC cell line heterozygous for rs6983267) identified a strong and specific signal for TCF7L2 binding coincident with the risk region ( Supplementary Fig. 2 ).
We used a mass spectrometry-based platform to quantify the relative abundance of G and T alleles in TCF7L2 immunoprecipitates from heterozygous LS174T cells. This technology can accurately measure the ratio of allelic peak heights, a reliable proxy for relative allelic load (Supplementary Methods). The G allele was significantly overrepresented in TCF7L2 immunoprecipated DNA but not in the input (P ¼ 1.14 Â 10 À5 ), demonstrating differential and increased binding of TCF7L2 to the risk allele at rs6983267 ( Fig. 1d ).
MYC is one of the strongest candidate genes in the 8q24 region. MYC is a target of the Wnt signaling pathway, a key pathway in CRC pathogenesis 11, 12 . Notably, solitary deletion of MYC rescues the tumor phenotype that follows APC gene deletion in mice, establishing MYC as a critical mediator of early steps in Wnt pathway-mediated colorectal tumorigenesis 13 . A previous study found no association between MYC protein expression in tumors and risk allele status 2 . Likewise, we found no association between rs6983267 and MYC mRNA expression in either normal colon or paired tumor samples in 110 individuals ( Supplementary Fig. 3 ).
Steady state levels of RNA or protein at a single time point may not adequately capture MYC's role in tumorigenesis. Because the magnitude of risk elevation is modest for common alleles and the clinical expression of disease is relatively late in life, expression differences driving risk can occur at any time point before the disease onset. Moreover, expression differences may only be present in a subpopulation of cells (for example, stem cells). Therefore, we sought complementary methods to examine MYC's role in CRC etiology.
Although the MYC gene lies at a considerable linear DNA distance from rs6983267, we posited that the enhancer region physically interacts with the MYC locus and used the chromosome conformation capture (3C) technique to test this hypothesis. This technique assesses whether a candidate fragment (for example, the MYC promoter) interacts physically with a region of interest (for example, the genomic region that contains rs6983267) 14 . To rigorously quantify ligation fragments, we used a novel competitive PCR approach using the Sequenom platform (Supplementary Methods and Supplementary  Figs. 4 and 5) .
We interrogated a constant fragment containing rs6983267 against a series of ten target fragments ( Fig. 2a) in two heterozygous CRC cell lines (Colo205 and LS174T) as well as in a control fibroblast cell line (LL24) homozygous (GG) for the risk variant. As expected, we observed increased interaction frequency between the constant and the adjacent fragment (3 kb) in both the CRC cell lines as well as the fibroblast line; such interaction was almost completely absent by fragment 3, located 95 kb away (Fig. 2b) . In CRC lines, we observed strong interactions between rs6983267 and fragments encompassing the promoter and the first half of MYC (fragments 4, 5 and 6) ( Fig. 2b) but not in the fibroblast line ( Supplementary Fig. 6) . Notably, the magnitude of the peak interaction between the rs6983267 and MYC regions in CRC lines was as abundant as that between rs6983267 and its adjacent fragment 1. Thus, the rs6983267 risk region physically interacts with MYC in CRC cell lines and does so in a tissue-specific manner. Further experiments analyzing 3C interactions by genotypic status may be informative.
We have demonstrated that the CRC risk locus containing rs6983267 has in vitro and in vivo properties of an enhancer and shows long-range physical interaction with MYC. We propose that this risk locus acts as part of a cis-regulatory enhancer element for the MYC proto-oncogene in CRC, mediating CRC risk in part through its differential binding with TCF7L2. As additional loci on 8q24 are The results demonstrate decreased interaction at 12 kb, 95 kb (fragments 2 and 3) and 395 kb (fragment 10), and increased interaction frequency in CRC cell lines at the MYC promoter (fragment 4) and the first half of the MYC structural gene (fragments 5 and 6), located B330 kb away. Distance from rs6983267 (x axis) is not represented to scale. The y axis refers to number of molecules in 3C libraries from each interrogated ligation product. Labels above each data point in the graph refer to the name of each target fragment 1-10.
known to be associated with other cancers 15 , it will be informative to evaluate whether these other 8q24 risk loci also interact with MYC. More broadly, this integrative approach offers a framework for understanding the molecular consequences of non-protein-coding risk alleles.
Note: Supplementary information is available on the Nature Genetics website.
